Chongqing Zhifei Biological Products Co Ltd (Zhifei Biological) is a manufacturer of vaccine products. It carries out the research and development production and sales of vaccines and biological products. Its vaccine portfolio includes Haemophilus influenzae type B conjugate vaccine, meningococcal group A and B polysaccharide vaccine, meningococcal group A and C conjugate vaccine, meningococcal groups A and C Haemophilus b conjugate vaccine. The company also offers human papillomavirus, valent pneumococcal polysaccharide, quadrivalent human papillomavirus and oral pentavalent reassortant rotavirus live attenuated vaccines, among others. Zhifei Biological also provides cold chain storage and transportation. It markets its vaccines under the brands Vikant, Gardash, Newmofa, GARDASIL, Leerde and Vaccae. Zhifei Biological is headquartered in Chongqing, Chongqing, China.
Headquarters
China
Address
50f, No. 1 Qingyun Road, Jiangbei District, Chongqing, 400020
Website
www.zhifeishengwu.com
Telephone
86 23 86358226
No of Employees
5,735
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300122 (SHE)
Revenue (2021)
$5.7B
24.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-26.2%
(2021 vs 2020)
Market Cap*
$13.4B
Net Profit Margin (2021)
XYZ
-40.8%
(2021 vs 2020)
* As of and is in US$
Chongqing Zhifei Biological Products Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Recombinant Novel Coronavirus Vaccine | Logistics, Distribution and Trade | Vikant |
| Recombinant Mycobacterium Tuberculosis Fusion Protein | Warehousing and Supply chain | Gardash |
| Haemophilus Influenzae Type B Conjugate Vaccine | Newmofa | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In November, the company announced plans to acquire Chenan Biopharmaceutical. |
| 2023 | Contracts/Agreements | In October, the company was selected by GSK to co-promote its shingles vaccine Shingrix in China. |
| 2022 | Contracts/Agreements | In April, Zhifei Luzhu signed a vaccine development and licensing agreement with Intravacc to cooperate to develop a new type of pertussis vaccine. |
Competitor Comparison
| Key Parameters | Chongqing Zhifei Biological Products Co Ltd | Beijing Tiantan Biological Products Co Ltd | Anhui Anke Biotechnology (Group) Co Ltd | Jiangsu Sihuan Bioengineering Co Ltd | Biomics Biotechnologies Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Chongqing | Beijing | Hefei | Wuxi | Nantong |
| State/Province | Chongqing | Beijing | Anhui | Jiangsu | Jiangsu |
| No. of Employees | 5,735 | 4,858 | 2,986 | 250 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jiang Rensheng | Chairman; General Manager | Executive Board | 2009 | 70 |
| Jiang Lingfeng | Vice Chairman | Executive Board | 2018 | 43 |
| Li Zhenjing | Director; Chief Financial Officer; Vice President | Executive Board | 2018 | 41 |
| Qin Fei | Secretary; Director; Vice President | Executive Board | 2021 | 37 |
| Wang Zhijun | Chief - Engineer | Senior Management | 2019 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward